Value of serum S-100B for prediction of distant relapse and survival in stage III B/C melanoma

Anticancer Research

Volumn 28, Issue 4 C, 2008, Pages 2297-2302

  Smit, L H M ^a,b   Nieweg, O E ^a   Mooi, W J ^a   Bonfrer, J M G ^a   Haanen, J B A G ^a   Kroon, B B R ^a   De Gast, G C ^a  

^a ANTONI VAN LEEUWENHOEK HOSPITAL   (Netherlands)

^b Department of Surgery ^*  (Netherlands)

Author keywords

Melanoma; Prediction; Relapse; S 100B; Stage IIIB C; Survival

Indexed keywords

BIOLOGICAL MARKER; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; INTRON-A; PROTEIN S100B; RECOMBINANT ALPHA2B INTERFERON; RECOMBINANT GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; RECOMBINANT INTERLEUKIN 2; TEMOZOLOMIDE;

ADJUVANT CHEMOTHERAPY; ARTICLE; CANCER ADJUVANT THERAPY; CANCER RELAPSE; CANCER STAGING; CANCER SURGERY; CANCER SURVIVAL; CLINICAL ARTICLE; CORRELATION ANALYSIS; DIAGNOSTIC VALUE; HUMAN; IMMUNOTHERAPY; MELANOMA; MONITORING; OVERALL SURVIVAL; PREDICTION; PRIORITY JOURNAL; PROSPECTIVE STUDY; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; REMISSION; STATISTICAL SIGNIFICANCE; TREATMENT RESPONSE;

CHEMOTHERAPY, ADJUVANT; HUMANS; IMMUNOHISTOCHEMISTRY; IMMUNOTHERAPY; LYMPH NODES; MELANOMA; NEOADJUVANT THERAPY; NEOPLASM STAGING; NERVE GROWTH FACTORS; S100 PROTEINS; TUMOR MARKERS, BIOLOGICAL;

EID: 48849116980     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (27)

1. Moore BW: A soluble protein characteristic of the nervous system. Biochem Biophys Res Commun 19: 739-744, 1965.
2. Isobe T and Okuyama T: The amino-acid sequence of the alpha subunit in bovine brain S-100a protein. Eur J Biochem 116: 79-86, 1981.
3. 2+ binding on S100B protein. J Biol Chem 261: 8192-8203, 1986.
4. Harpio R and Einarsson R: S100 proteins as cancer biomarkers with focus on S100B in malignant melanoma. Clin Biochem 37: 512-518, 2004.
5. Schafer BW, Wicki R, Engelkamp D et al: Isolation of a YAC clone covering a cluster of nine S100 genes on human chromosome Iq21: rationale for a new nomenclature of the S100 calcium-binding protein family. Genomics 25: 638-643, 1995.
6. Fagnart OC, Sindic CJ and Laterre C: Particle counting immunoassay of S100 protein in serum. Possible relevance in tumors and ischemic disorders of the central nervous system. Clin Chem 34: 1387-1391, 1988.
7. Bonfrer JMG, Korse CM, Nieweg OE and Rankin EM: The luminescence immunoassay S-100: a sensitive test to measure circulating S-100B: its prognostic value in malignant melanoma. Br J Cancer 77: 2210-2214, 1998.
8. Hamberg AP, Korse CM, Bonfrer JMG and de Gast GC: Serum S100B is suitable for prediction and monitoring of response to chemoimmunotherapy in metastatic malignant melanoma. Melanoma Res 13: 45-49, 2003.
9. Domingo-Domenech J, Castel T, Auge JM et al: Prognostic implications of protein S-100beta serum levels in clinical outcome of high-risk melanoma patients. Tumour Biol 28(5): 264-272, 2007.
10. Smit LHM, Korse CM, Hart AAM et al: Normal values of serum S-100B predict prolonged survival for stage IV melanoma patients. Eur J Cancer 41: 386-392, 2005.
11. Acland KM, Evans AV, Abraha HD et al: Serum S100 concentrations are not useful in predicting micrometastatic disease in cutaneous malignant melanoma. Br J Dermatol 146: 832-835, 2002.
12. Smit LHM, Nieweg OE, Korse CM et al: Significance of serum S-100B in melanoma patients before and after sentinel node biopsy. J Surg Oncol 90: 66-69, 2005.
13. Balch CM, Buzaid AC, Soong SJ et al: Final version of the American Joint Committee on Cancer staging system for cutaneous melanoma. J Clin Oncol 19: 3635-3648, 2001.
14. Vrouenraets BC, Nieweg OE and Kroon BBR: Thirty-five years of isolated limb perfusion for melanoma: indications and results. Br J Surg 83: 1319-1328, 1996.
15. Eggermont AM: Adjuvant therapy in melanoma (abstract). Suppl Eur J Cancer 1: S107 (348), 2003.
16. Kirkwood JM, Strawderman MH, Ernstoff MS et al: Interferon alfa-2b adjuvant therapy of high-risk resected cutaneous melanoma: the Eastern Cooperative Oncology Group Trial EST 1684. J Clin Oncol 14: 7-17, 1996.
17. Kirkwood JM, Ibrahim JG, Sondak VK et al: High- and low-dose interferon alfa-2b in high-risk melanoma: first analysis of intergroup trial E1690/S9111/C9190. J Clin Oncol 18: 2444-2458, 2000.
18. Kirkwood JM, Ibrahim JG, Sosman JA et al: High-dose interferon alfa-2b significantly prolongs relapse-free and overall survival compared with the GM2-KLH/QS-21 vaccine in patients with resected stage IIB-III melanoma: results of intergroup trial E1694/S9512/C509801. J Clin Oncol 19: 2370-2380, 2001.
19. Buzaid AC, Legha SS, Balch CM et al: Pilot study of preoperative chemotherapy with cisplatin, vinblastine, and dacarbazine in patients with local-regional recurrence of melanoma. Cancer 74: 2476-2482, 1994.
20. Buzaid AC, Colome M, Bedikian A et al: Phase II study of neoadjuvant concurrent biochemotherapy in melanoma patients with local-regional metastases. Melanoma Res 8: 549-556,1998.
21. Gibbs P, Anderson C, Pearlman N et al: A phase II study of neoadjuvant biochemotherapy for stage III melanoma. Cancer 94: 470-476, 2002.
22. Mooi WJ and Krausz T: Cytological diagnosis of melanoma. In: Biopsy Pathology of Melanocytic Disorders. Mooi WJ and Krausz T (eds.). London: Chapman Hall Medical, pp. 404-420, 1993.
23. Banfalvi T, Udvarhelyi N, Orosz Z et al: Heterogenous S-100B protein expression patterns in malignant melanoma and association with serum protein levels. Oncology 64: 374-379, 2003.
24. Deichmann M, Benner A, Bock M et al: S100-Beta, melanomainhibiting activity, and lactate dehydrogenase discriminate progressive from nonprogressive American Joint Committee on Cancer stage IV melanoma. J Clin Oncol 17: 1891-1896, 1999.
25. Garnier JP, Letellier S, Cassinat B et al: Clinical value of combined determination of plasma L-DOPA/tyrosine ratio, S100B, MIA and LDH in melanoma. Eur J Cancer 43(4): 816-821, 2007.
26. Krahn G, Kaskel P, Sander S et al: S100 beta is a more reliable tumor marker in peripheral blood for patients with newly occurred melanoma metastases compared with MIA, albumin and lactate-dehydrogenase. Anticancer Res 21: 1311-1316, 2001.
27. Hagen EC, Vennegoor C, Schlingemann RO et al: Correlation of histopathological characteristics with staining patterns in human melanoma assessed by (monoclonal) antibodies reactive on paraffin sections. Histopathology 10: 689-700, 1986.